Diamond Therapeutics has received approval from Health Canada to carry out a Phase 2 low-dose psilocybin trial for the treatment of generalised anxiety disorder (GAD) on...
Small Pharma has reported positive top-line results from its Phase 2a Trial of SPL026 in Major Depressive Disorder (MDD).
Awakn Life Sciences has initiated an investigative study to establish the dissociative effect of a proprietary and patent pending formulation of (S)-ketamine and an optimised route...
Cybin has announced key highlights from its study evaluating Kernel’s Flow wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.
The Energia Foundation, an organisation working at the forefront of healthcare and social movements, hosted the House of Health in Davos, Switzerland from 15 to 20...
Psyence Group has confirmed that it has exported purified pharmaceutical-grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation (CDMO) partner in the UK.
Results from MAPS PBC’s study have demonstrated a biological correlation between a reduction in PTSD severity and treatment with MDMA-assisted therapy in veterans and first responders.
Peter Reitano, CEO of Gwella, speaks to Psychedelic Health about the company’s mission to provide education on psychedelics and raise acceptance of the compounds beyond mental...
In this article, Kath Temple, Psychologist at healthy living and aging platform, Goldster, who has recently been working alongside addiction and trauma expert Dr Gabor Maté,...
Incannex Healthcare has confirmed that its PsiGAD1 clinical trial has achieved its interim milestone of 29 patients completing primary endpoint assessments.